Literature DB >> 25837606

Combined conjunctival rotational autograft with 0.02% mitomycin C in primary pterygium surgery: a long-term follow-up study.

Nicole C Tsim1, Alvin L Young1, Vishal Jhanji1, Mary Ho1, Lulu L Cheng1.   

Abstract

BACKGROUND/AIMS: To compare the long-term outcomes of primary pterygium surgery with combined conjunctival rotational autograft and mitomycin C (CRA-MMC), mitomycin C alone (MMC) and limbal conjunctival autograft (LCAU).
METHODS: The outcomes of primary pterygium excision followed by conjunctival rotational autograft (CRA) combined with intraoperative 0.02% MMC for 5 min (group 1, CRA-MMC, n=61) were compared with historical control groups consisting of, pterygium excision with MMC (group 2, n=47), and, pterygium excision with limbal conjunctival autograft (LCAU) (group 3, n=29). The main outcome measures were recurrence rate and complications.
RESULTS: The mean follow-up period was 101±3 months, 138±2 and 137±2 months in the CRA-MMC, MMC and LCAU groups respectively. Recurrence was noted in one patient (1.6%) in the CRA-MMC, 12 patients with MMC (25.5%) and 2 patients with LCAU (6.9%). The difference in recurrence rate between CRA-MMC and MMC was statistically significant (p<0.001). Early postoperative complications included 3 conjunctival cysts (1 from the CRA-MMC, 2 with MMC alone), 2 symblephara (1 in the MMC group, 1 in the LCAU group), and 1 granuloma in the CRA-MMC group.
CONCLUSIONS: Pterygium excision followed by CRA-MMC or LCAU are effective means of preventing recurrence. The use of CRA-MMC in pterygium excision may be considered for cases where conventional autograft harvesting is contraindicated or when large grafts for double-head pterygium are required. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Cornea; Degeneration; Treatment Surgery

Mesh:

Substances:

Year:  2015        PMID: 25837606     DOI: 10.1136/bjophthalmol-2014-305817

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  5 in total

1.  A novel graft option after pterygium excision: platelet-rich fibrin for conjunctivoplasty.

Authors:  H B Cakmak; G Dereli Can; M E Can; N Cagil
Journal:  Eye (Lond)       Date:  2017-06-16       Impact factor: 3.775

2.  [Should mitomycin C be used routinely in pterygium surgery?]

Authors:  K Eisenmann; F Zeman; H Helbig; M-A Gamulescu; T Barth
Journal:  Ophthalmologe       Date:  2020-04       Impact factor: 1.059

3.  Fifteen-year results of a randomized controlled trial comparing 0.02% mitomycin C, limbal conjunctival autograft, and combined mitomycin C with limbal conjunctival autograft in recurrent pterygium surgery.

Authors:  Ka Wai Kam; Alvin L Young
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-10-24       Impact factor: 3.117

Review 4.  Recurrent Pterygium: A Review.

Authors:  Leila Ghiasian; Bijan Samavat; Yasaman Hadi; Mona Arbab; Navid Abolfathzadeh
Journal:  J Curr Ophthalmol       Date:  2022-01-06

5.  Outcomes of Vertical Split Conjunctival Autograft Using Fibrin Glue in Treatment of Primary Double-Headed Pterygia.

Authors:  Tarek Roshdy Elhamaky; Ahmed Mohammed Elbarky
Journal:  J Ophthalmol       Date:  2018-12-20       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.